1. De Backer O, Bieliauskas G, Søndergaard L. Current status and future perspectives for transcatheter and surgical aortic valve replacement: the role of aortic valve surgery in the era of transcatheter-based therapies. EuroIntervention. 2018;14(9):e965-7. 
2. Deutsch MA, Scotten LN, Siegel R, Lange R, Bleiziffer S. Leaflet thrombosis and clinical events after TAVR: are paravalvular leaks a crucial trigger? EuroIntervention. 2018;14(6):716-7. 
3. Rashid HN, Cameron JD, Brown AJ. Activation of the coagulation cascade and the role of paravalvular leak in the development of leaflet thrombosis following transcatheter aortic valve replacement. EuroIntervention. 2018;14(6):718-9. 
4. Vavuranakis M, Kalogeras K, Kolokathis AM, Vrachatis D, Magkoutis N, Siasos G, et al. Antithrombotic therapy in TAVI. J Geriatr Cardiol. 2018;15(1):66-75. 
5. Mylotte D, Andalib A, Thériault-Lauzier P, Dorfmeister M, Girgis M, Alharbi W, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2015;36(21):1306-27. 
6. Ruparelia N. Oral Anticoagulant Therapy for Early Post-TAVI Thrombosis. Interv Cardiol. 2018;13(1):33-6. 
7. Testa L, Latib A. Assessing the Risk of Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. Interv Cardiol. 2018;13(1):37-9. 
